SITABASE M 50/500
Description
- Fixed-dose combination of Sitagliptin 50 mg and Metformin 500 mg.
- Sitagliptin enhances insulin secretion and inhibits glucagon release.
- Metformin decreases liver glucose production and improves insulin sensitivity.
- Effective in controlling both fasting and post-meal blood sugar levels.
- Lowers risk of hypoglycemia when used as prescribed.
- Supports weight management and improves metabolic parameters.
- Convenient oral dosing for improved adherence.
- Suitable as monotherapy or with other antidiabetic agents under medical supervision.
Composition
SITAGLIPTIN PHOSPHATE MONOHYDRATE-50 MG, METFORMIN HYDROCHLORIDE-500 MG
Benefits
SITABASE M 50/500 offers comprehensive blood sugar control by combining the glucose-lowering effects of Metformin and the incretin-enhancing action of Sitagliptin. This combination helps reduce fasting and postprandial blood glucose levels, supports weight management, and lowers the risk of hypoglycemia compared to some other antidiabetic therapies. Its once- or twice-daily dosing enhances patient compliance, making it an ideal choice for effective management of type 2 diabetes alongside lifestyle modifications.
Introduction
SITABASE M 50/500 is a combination oral antidiabetic medication containing Sitagliptin Phosphate Monohydrate 50 mg and Metformin Hydrochloride 500 mg, formulated to improve glycemic control in patients with type 2 diabetes mellitus. Sitagliptin, a DPP-4 inhibitor, increases incretin hormone levels, which help regulate insulin and glucagon secretion, while Metformin, a biguanide, reduces hepatic glucose production and improves insulin sensitivity. Together, they provide complementary mechanisms to effectively lower blood glucose levels and support overall diabetes management.
